Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nymox Pharmaceutical Corporation stock

Own Nymox Pharmaceutical Corporation stock in just a few minutes.

Nymox Pharmaceutical Corporation is a biotechnology business based in the US. Nymox Pharmaceutical Corporation shares (NYMX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Nymox Pharmaceutical Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NYMX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Nymox Pharmaceutical Corporation share price

Use our graph to track the performance of NYMX stocks over time.

Nymox Pharmaceutical Corporation shares at a glance

Information last updated 2021-03-10.
52-week range$1.66 - $4.79
50-day moving average $2.71
200-day moving average $2.43
Wall St. target price$10.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.21

Buy Nymox Pharmaceutical Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nymox Pharmaceutical Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nymox Pharmaceutical Corporation financials

Revenue TTM $31,000
Gross profit TTM $58,000
Return on assets TTM -117.52%
Return on equity TTM -261.18%
Profit margin 0%
Book value $0.05
Market capitalisation $202.3 million

TTM: trailing 12 months

Shorting Nymox Pharmaceutical Corporation shares

There are currently 3.8 million Nymox Pharmaceutical Corporation shares held short by investors – that's known as Nymox Pharmaceutical Corporation's "short interest". This figure is 2.3% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting Nymox Pharmaceutical Corporation shares can be evaluated.

Nymox Pharmaceutical Corporation's "short interest ratio" (SIR)

Nymox Pharmaceutical Corporation's "short interest ratio" (SIR) is the quantity of Nymox Pharmaceutical Corporation shares currently shorted divided by the average quantity of Nymox Pharmaceutical Corporation shares traded daily (recently around 197204.26638918). Nymox Pharmaceutical Corporation's SIR currently stands at 19.22. In other words for every 100,000 Nymox Pharmaceutical Corporation shares traded daily on the market, roughly 19220 shares are currently held short.

However Nymox Pharmaceutical Corporation's short interest can also be evaluated against the total number of Nymox Pharmaceutical Corporation shares, or, against the total number of tradable Nymox Pharmaceutical Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nymox Pharmaceutical Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Nymox Pharmaceutical Corporation shares in existence, roughly 50 shares are currently held short) or 0.083% of the tradable shares (for every 100,000 tradable Nymox Pharmaceutical Corporation shares, roughly 83 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Nymox Pharmaceutical Corporation.

Find out more about how you can short Nymox Pharmaceutical Corporation stock.

Nymox Pharmaceutical Corporation share dividends

We're not expecting Nymox Pharmaceutical Corporation to pay a dividend over the next 12 months.

Nymox Pharmaceutical Corporation share price volatility

Over the last 12 months, Nymox Pharmaceutical Corporation's shares have ranged in value from as little as $1.66 up to $4.79. A popular way to gauge a stock's volatility is its "beta".

NYMX.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nymox Pharmaceutical Corporation's is 1.4935. This would suggest that Nymox Pharmaceutical Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nymox Pharmaceutical Corporation overview

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company operates in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site